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Summary: In a time study we compared the analytical and clinical performance of the Tandem Icon QSR
CK-MB enzyme-immunoassay (Hybritech) (creatine kinase-MB) and a creatine kinase-MB immunoinhibition
method (Boehringer Mannheim GmbH) (creatine kinase-B). Two hundred and ninety-nine serum samples
from 38 patients suspected of acute myocardial infarction were collected at regular intervals during 48 hours.
Twenty-nine patients were diagnosed as having acute myocardial infarction, of whom 19 recieved thrombolytic
therapy. Although highly correlated, the large scatter around the regression line at low values indicated a
different clinical performance of the two methods. We evaluated and compared test performance at different
decision levels by means of frequency distributions and predictive values of positive and negative results. For
early diagnosis of acute myocardial infarction (4 hours after onset of pain) the Hybritech creatine kinase-MB
method gives acceptable predictive values. In thrombolytic treated acute myocardial infarction patients, the
peak creatine kinase-MB and creatine kinase-B concentrations were reached after 13.0 h and 13.6 h after the
onset of pain, compared with 19.8 h and 17.8 h for patients without thrombolytic therapy.
The three most common groups of methods for meas-
Thrombolytic therapy in patients with acute myocar- urement of creatine kinase isoenzymes are: separation
dial infarction is now standard treatment (1, 2) and methods (electrophoresis, ion-exchange chromato-
is most effective when started as soon as possible after graphy) and immunoprecipitation and immunoinhi-
onset of symptoms. Therefore an early diagnostic test bition methods, which all measure catalytic activity,
in patients with suspected acute myocardial infarction and specific antibody immunoassays which measure
is important. The standard laboratory procedures mass concentration (6 —9).
(3 — 5) are measurement of enzymes, especially crea- T . , ι ^ j ^ ^ , T /-.on\ , . . 1N . ._ , ' / / In a time study we evaluated the Tandem Icon QSRtine kinase isoenzyme ) MB, released from the nee- ^__ . __. /TT t . ,. , . , . x,·^ ,J ' CK-MB assay (Hybritech) (creatine kinase-MB) androtic myocardium. Al .. Λ ,~ . . ,.,.,. ., Λthe creatine kinase-MB immunoinhibition method
(Boehringer) (creatine kinase-B) in 299 samples from
38 patients suspected of acute myocardial infarction,
*) Study-group members: with respect to predictive values of positive and neg-
Erik Kj011er, Finn Nielsen, J0rn Carlsen, Knud Skagen, ative results at different decision limits (frequency
Steen Levin Nielsen, Inge-Lis Kanstrup, Keld Hvid-Jacob- ,. ., · x TT · ^ ^ A I _ J · *· * Λsen, Jacob Trier M011er, Per F0ge Jensen. distribution). Using both methods, we investigated
') Enzyme: Creatine kinase (EC 2.7.3.2) isoenzyme MB. the influence of thrombolytic therapy on the time
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taken to attain peak values (time to peak) in 29 acute
myocardial infarction patients, of whom 19 had re-
ceived thrombolytic therapy.
low (mean 5 μg/l); N = 10) patient serum pool were
6% and 15% respectively. Creatine kinase-B between-
assay CV was 5% (mean 40 U/l, N = 12) and 25%
(mean 10 U/l, N = 38).
Materials and Methods
Analy t i ca l methods
Creatine kinase-MB mass concentration was assayed with the
Tandem Icon QSR CK-MB quantitative test (Hybritech Inc.,
San Diego, California) as specified by the manufacturer. This
assay is specific for creatine kinase-MB isoenzyme and uses two
monoclonal antibodies, one binding to the M-subunit and the
other to the B-subunit of the creatine kinase-MB molecule.
Each test cylinder contains test zones for low and high calibra-
tor and for duplicate sample. Results were measured on a
reflectometer (Hybritech Icon Reader). The detection limit was
2 μg/l (manufacturer's specifications).
Creatine kinase-MB catalytic activity (creatine kinase-B) was
assayed with creatine kinase-MB (N-acetyl cysteine (NAQ-
activated) reagents (Boehringer Mannheim GmbH Diagnostica,
Mannheim, Germany) at 37 °C (our routine laboratory
method). After selective inhibition of the creatine kinase-M
subunit, the residual creatine kinase-B activity was measured.
Results were corrected for adenylate kinase activity. This assay
also measures creatine kinase-BB and macro creatine kinase (7)
when present. The method was adapted to the RA 1000 au-
toanalyser (Technicon Instruments Corporation, Tarrytown,
USA).
Pat ients
We assayed 299 blood samples from 38 patients. Blood was
collected from the antecubital vein at approximately 0, 3, 6, 9,
12, 18, 24, 36 and 48 hours after admission. For some patients
the sample series were not complete. The samples were centri-
fuged and serum was stored at 4—8 °C for measurement of
creatine kinase-B within 24 hours in our in-house routine assay,
and at —70 °C for measurement of creatine kinase-MB within
2 months.
All samples assayed were from patients admitted to the coro-
nary care unit with acute ischaemic syndrome and included in
the Myocardioscintigraphy in Acute Ischaemic Syndrome pro-
ject. The diagnosis of acute myocardial infarction was estab-
lished on the basis of clinical history, daily 12-lead electrocar-
diogram and enzyme results, not including creatine kinase-B
and creatine kinase-MB. Twenty-nine patients were diagnosed
as having acute myocardial infarction, and 19 of these recieved
thrombolytic therapy (streptokinase 1.5 χ ΙΟ6 IU).
The patients were admitted 3/4 hours (mean) (range 2!/2 to 14
hours) after the onset of pain. In 26 of the patients the first
blood sample was collected within 4 hours after onset of pain
and in 9 patients the first sample was collected so close to 4
hours that extrapolation from the time curve could be applied.
Analytical correlation
The correlation between creatine kinase-MB mass
concentration (y) and creatine kinase-MB enzyme cat-
alytic activity (x) is shown in figure 1. The regression
equation was: y = 2.078 χ - 13.826, r = 0.946; SytX
= 15.014. The mean specific enzyme activity (x/y)
was 560 U/mg. A considerable scatter of the data is
observed in the low range (fig. 1, insert), due to the
high CV of the creatine kinase-B method at low
values. For values < 50 μg/l (U/l) the regression
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Fig. 1. Correlation between creatine kinase-MB enzyme activ-
ity (creatine kinase-B) and creatine kinase-MB mass
concentration (creatine kinase-MB) in serum samples
from 38 patients suspected of acute myocardial infarc-
tion.
56 results were below the detection limit of the creatine
kinase-MB method (2 μ§/1) and were not included in
the calculation. Solid line: 100% correlation line; dotted
lines: standard error of the estimate (± Sy(X). Insert
shows values < 50 μg/l (U/l).
Statistical method
Demings correlation test was used for comparison of creatine
kinase-B and creatine kinase-MB results (10).
Results
Analytical imprecision
Creatine kinase-MB between-assay coefficient of var-
iation (CV) for a high (mean 21 μg/l; Ν = 10) and a
Frequency distribution
Histograms (11) for test results were drawn for both
tests (fig. 2a and 2b). At 4 and 8 hours after onset of
pain and at peak enzyme concentration, the predictive
values of positive (PVpos) and negative (PVneg) test
results were calculated at decision limits 2, 6, 12, 20
and 30 μg/l for creatine kinase-MB and 2, 6, 9, 12,
20, 30, 50 and 60 U/l for creatine kinase-B. The 8-
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•20 hour values were similar to the peak values and there-
.15 fore not shown.
-10 As observed both a peak values and at four hours,
5 the creatine kinase-MB test showed highest PVpos at
all decision limits. At four hours, PVpos > 0.9 and a
^ PVneg > 0.75 were obtained at the decision limit of
"^ c 2 ug/1 for creatine kinase-MB. A similar PVpos wasω . . . . . . .•10 -^ obtained for creatine kinase-B at the decision limit of
β 1" 12 U/l, however with PVneg < 0.5.
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•15 J§ Time course of creatine kinase-MB and crea-
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_5 After admission to hospital, 38 patients were followed
with blood sampling during a 48-hour period (range
20 — 84 hours). For 29 patients with acute myocardial
•5 infarction, 19 receiving (a) and 10 not receiving
.10 thrombolytic therapy (b), curves were drawn for crea-
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Fig. 2a, b. Frequency distribution based on creatine kinase-B
(upper field) and creatine kinase-MB (lower field)
peak values (a) for 29 acute myocardial infarctions
(AMI; hatched bars) and 9 non-acute myocardial
infarctions (non-AMI; open bars) cases and 4-hour
values (b) for 26 acute myocardial infarction
(hatched bars) and 9 non-acute myocardial infarc-
tion (open bars) cases. Right ordinate: number of
cases.
All values > 90 U/l (μ§/1) are included in the 90-
100 bar.
PVpos ( ) and PVneg ( ) curves are plotted
(scale left ordinate).
Fig. 3. Time-course of creatine kinase-MB mass concentration
in serum samples from 19 acute myocardial infarction
patients treated with thrombolytic therapy (a) and in
10 acute myocardial infarction patients without throm-
bolytic therapy (b).
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Fig. 4. Time-course of creatine kinase-B enzyme activity in
serum samples from 19 acute myocardial infarction
patients treated with thrombolytic therapy (a) and in
10 acute myocardial infarction patients without throm-
bolytic therapy (b).
tine kinase-MB (fig. 3a and 3b) and creatine kinase-B
(fig. 4a and 4b), using the onset of pain as time zero.
Using the decision limit 9 μg/l for creatine kinase-MB
and 20 U/l for creatine kinase-B we found that in the
patients receiving thrombolytic therapy, the duration
of positive creatine kinase-MB was 48.3 h (16 — 72)
compared with 43.0 h (23 — 65) for creatine kinase-B
(NS). Time to peak was 13.0 h (2.5-26.0) for creatine
kinase-MB, compared with 13.6 h (3.0-26.0) for
creatine kinase-B (NS). In the patients who did not
receive thrombolytic therapy, the duration of positive
test results was 51.6 h (42 — 68) for creatine kinase-
MB and 31.5 h (17-46) for creatine kinase-B
(p < 0.01). Time to peak was 19.8 h (10-45) for
creatine kinase-MB, compared with 17.8 h (10—42)
for creatine kinase-B (NS).
Although both methods gave different mean values
for the time to peak in patients with and without
thrombolytic treatment, this was not statistically sig-
nificant, and probably the result of using a small
number of patients.
Discussion
Our objectives were to investigate the conceivable
advantage in using one of the new specific tests for
creatine kinase-MB, especially in the early diagnosis
of acute myocardial infarction, which may support
the use of thrombolytic therapy of acute myocardial
infarction (7).
As observed, the creatine kinase-MB mass concentra-
tion and the creatine kinase-MB enzyme activity cor-
related well for elevated enzyme concentrations, in
agreement with other studies (12, 13). We did not
multiply our enzyme activity results by a factor 2 (to
compensate for the blocking of the M-subunit), which
explains the lower specific activity in our study com-
pared with others. However, at low values (< 50 U/l)
the correlation was poor (note the large scatter at low
values in figure 1 (insert)), due to the high imprecision
of both tests in this range, especially the creatine
kinase-B.
The frequency distribution histograms showed that
the creatine kinase-MB mass concentration assay
could be used in early diagnosis (4 hours after onset
of pain) with a PVpos greater than 0.9, combined
with a PVneg greater than 0.75, which was never
obtained for the creatine kinase-MB activity method.
At the enzyme peak concentration, comparable pre-
dictive values were obtained for both methods. At the
peak concentration, acceptable clinical performance
was obtained for the creatine kinase-MB activity
method, using the decision limits of 12 and 20 U/l.
At 8 hours after the onset of pain the performance
characteristics for both methods were very similar to
those at enzyme peak concentrations (not shown).
Based on the decision limits of 9 μg/l for creatine
kinase-MB and 20 U/l for creatine kinase-B, the du-
ration time for the positive test in patients who not
receiving thrombolytic therapy was significantly
longer for creatine kinase-MB than for creatine ki-
nase-B. In patients receiving thrombolytic therapy,
the duration time for both methods was not signifi-
cantly different.
In agreement with other studies (14, 15), both meth-
ods showed a difference in time to peak between
thrombolytic treated patients and non-treated pa-
tients; but in our study this difference was not signif-
icant (p < 0.1 for creatine kinase-MB and p < 0.25
for creatine kinase-B), probably due to the small
number of patients.
We conclude that both methods provide sufficient
predictive values for both positive and negative di-
agnosis of acute myocardial infarction at eight hours
after the onset of pain. The creatine kinase-MB also
gives acceptable predictive values for early diagnosis
(4 hours after onset of pain), which is claimed to be
crucial for successful thrombolytic therapy (1) and
may therefore be of value to the clinician as a diag-
nostic support in the treatment of acute myocardial
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 6
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infarction. The appropriate decision limits should be
chosen from the frequency distribution histograms,
with due consideration for the prevalence and the
costs of false results.
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